Skip to main content

A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatmentnaive metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186-Trials in progress

Publication ,  Conference
Dotan, E; Catalano, PJ; Lenchik, L; Boutin, R; Yao, X; Beg, SS; Vijayvergia, N; Gatsonis, C; Zhen, DB; Li, D; Wagner, LI; Simon, MA; Wong, TZ ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dotan, Efrat, Paul J. Catalano, Leon Lenchik, Robert Boutin, Xin Yao, Shaalan Shaalan Beg, Namrata Vijayvergia, et al. “A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatmentnaive metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186-Trials in progress.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Dotan E, Catalano PJ, Lenchik L, Boutin R, Yao X, Beg SS, Vijayvergia N, Gatsonis C, Zhen DB, Li D, Wagner LI, Simon MA, Wong TZ, O’Dwyer PJ. A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatmentnaive metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186-Trials in progress. JOURNAL OF CLINICAL ONCOLOGY. 2022.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences